<DOC>
	<DOCNO>NCT02205463</DOCNO>
	<brief_summary>This dose-escalation study determine safety , maximum tolerate dose ( MTD ) efficacy KD019 combination trastuzumab mFOLFOX-6 .</brief_summary>
	<brief_title>KD019 Trastuzumab Patients With Esophagus , Gastroesophageal Junction Stomach Cancer</brief_title>
	<detailed_description>This open-label , single-arm , dose-escalation phase Ib study determine safety , maximum tolerate dose ( MTD ) efficacy KD019 , multi kinase inhibitor EGFR , HER2 , Src VEGFR2 , combination trastuzumab mFOLFOX-6 patient human epidermal growth factor receptor 2 positive ( HER2+ ) metastatic unresectable adenocarcinoma esophagus , gastroesophageal junction stomach . Patients HER2+ metastatic unresectable adenocarcinoma esophagus , gastroesophageal junction stomach receive trastuzumab mFOLFOX-6 combination KD019 evaluate safety , toxicity maximum tolerate dose regimen . There four dose cohort KD019 . KD019 administer orally continuously daily 28 day cycle . Trastuzumab mFOLFOX-6 administer infusion every 2 week standard dos without escalation . The sequence day agent administer KD019 follow trastuzumab mFOLFOX-6 . Hypothesis A ) KD019 , small molecule inhibitor multiple receptor tyrosine kinases include EGFR , HER2 , VEGFR-2 Src , safely add , effective dose , every 2 week schedule mFOLFOX-6 + trastuzumab patient metastatic unresectable HER2+ adenocarcinoma esophagus , GEJ stomach B ) When add mFOLFOX-6 + trastuzumab , KD019will increase response duration , progression free survival Primary objective : To assess safety , tolerability , maximum tolerate dose ( MTD ) , recommend phase II dosing ( RP2D ) KD019 combination trastuzumab mFOLFOX-6 Secondary objective : 1 . To characterize pharmacokinetics ( PK ) parameter KD019 administer daily combination every 2 week mFOLFOX-6 trastuzumab subject metastatic unresectable HER2+ adenocarcinoma esophagus , gastroesophageal junction ( GEJ ) stomach . 2 . To evaluate tumor biopsy specimens pre- post- treatment KD019 trastuzumab change target receptor correlate response</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Patients must meet follow inclusion criterion eligible enrollment study : Pathologically confirm diagnosis adenocarcinoma stomach , GEJ esophagus ( central confirmation require ) . Primary tumor metastatic lesion must HER2+ document HER2 gene amplification FISH positive ( HER2 : CEP17 ratio ≥2.0 ) IHC 3+ . Metastatic unresectable adenocarcinoma stomach , GEJ , esophagus evaluable measurable response per RECIST 1.1 criterion , define least one lesion accurately measure least one dimension ( long diameter record ) &gt; 20 mm conventional technique &gt; 10 mm spiral compute tomography ( CT ) scan . Adult subject great 18 year age Patients receive postoperative adjuvant therapy singleagent fluoropyrimidine radiation eligible . Eastern cooperative oncology group ( ECOG ) performance status 0 1 . Adequate organ bone marrow function define follow : oAbsolute neutrophil count &gt; 1,500 cells/ul Platelets &gt; 100,000/ul Hemoglobin &gt; 9.0g/dl INR &lt; equal 1.5 INR &lt; equal 3 patient warfarin Serum creatinine &lt; equal 1.5 time upper limit normal ( ULN ) calculate creatinine clearance ( CRCL ) &gt; equal 60ml/min Serum electrolyte within normal range ( per institution standard ) screening . Total bilirubin less equal 1.5 time upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; equal 3 time ULN Albumin &gt; equal 3g/dL No history another malignancy past 5 year , except treat nonmelanoma skin cancer superficial bladder cancer carcinomainsitu cervix No coexist medical problem sufficient severity limit compliance study Ability understand sign write informed consent document . Patient must willingness ability comply schedule visit , treatment plan , laboratory test study procedure . Female subject childbearing potential must negative serum pregnancy test prior study entry ( positive urine test confirm serum test ) . Female subject childbearing potential male must agree use highly effective method contraception ( &lt; 1 % per year failure rate ) duration study treatment six month discontinuation study drug . Highly effective birth control method include implant , injectables , combine oral contraceptive , IUDs , sexual abstinence , vasectomy male . Prior treatment chemotherapy HER2directed therapy metastatic gastric , GEJ esophageal adenocarcinoma chemotherapy . Prior perioperative therapy platinumcontaining regimen . Angina secondary fluoropyrimidine therapy adjuvant setting Surgery , radiotherapy , lesion ablative procedure area measurable/evaluable disease . Major surgery within 4 week prior first dose KD019 Left ventricular ejection fraction ( EF ) &lt; 50 % baseline measure multigated acquisition ( MUGA ) scan echocardiogram ( ECHO ) . Treatment chronic immunosuppressant ( e.g . cyclosporine follow transplantation ) Current know active infection HIV , hepatitis B C viruses Uncontrolled systemic disease Brain metastasis : Untreated Progressive Have require type therapy ( include radiation , surgery , steroid anticonvulsant therapy ) control symptom brain metastasis within 60 day prior first study treatment Leptomeningeal Hemorrhagic Subject evidence preexist idiopathic pulmonary fibrosis CT scan baseline History invasive secondary primary malignancy diagnose within previous 3 year , except appropriately treat stage I endometrial cervical carcinoma , prostate carcinoma treat surgically nonmelanoma skin cancer . No nonprotocol antineoplastic agent permit study Patients may receive investigational agent . Women pregnant lactating . Subject follow EKG criterion : Corrected QT interval ( QTc ) &gt; 0.47 second Finding leave bundle branch block right bundle bunch block Bradycardia define heart rate &lt; 50 beat per minute ( bpm ) Presence pacemaker implantable cardioverter defibrillator ( ICD ) History sustain ventricular arrhythmia ( subject history atrial arrhythmia discuss sponsor entry study ) Family history congenital long QT syndrome unexplained sudden death . Moderate severe pulmonary dysfunction History clinically significant cardiac dysfunction include : Unstable angina History myocardial infarction ( MI ) within 6 month prior first study treatment History symptomatic CHF ( grade &gt; 3 NCI CTCAE Class &gt; II New York Heart Association ( NYHA ) criteria serious cardiac arrhythmia require treatment , exception atrial fibrillation paroxysmal supraventricular tachycardia Uncontrolled hypertension define systolic blood pressure ( SBP ) ≥ 160 and/or diastolic blood pressure ( DBP ) ≥ 100 despite maximal medical therapy . Subject require treatment drug know associated torsades de pointes significant QT interval prolongation . Patients eligible study discontinue medication list one week prior registration study enrollment . Stable regimen antidepressant SSRI class allow ( common SSRIs include escitalopram oxalate , citalopram , fluvoxamine , paroxetine , sertraline fluoxetine ) Use cytochrome P450 enzymeinducing antiepileptic drug ( phenytoin , carbamazepine phenobarbital ) allow . Subject serum potassium magnesium level outside normal range despite repletion . Has gastrointestinal tract disease result inability take absorb oral medication . Inclusion exclusion patient medication , severe acute/chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation study drug administration , may interfere interpretation study result judgment study investigator . Subject unable unwilling abide study protocol cooperate fully investigator designee .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Esophagus</keyword>
	<keyword>Gastroesophageal Junction</keyword>
	<keyword>Stomach</keyword>
	<keyword>Gastric</keyword>
	<keyword>Cancer</keyword>
	<keyword>HER2</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Adenocarcinoma</keyword>
</DOC>